Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX) has three new compounds in development, oral PRX-106 for immune mediated disorders, PRX-110 for Cystic Fibrosis (CF), and PRX-107 for emphysema from heredity alpha1-antitrypsin (AAT) deficiency. PRX-106 is the company’s proprietary plant cell recombinant Anti-TNF fusion protein being developed as an orally-administered treatment for immune...
Read more
About: Bio-Israel
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam libero diam, elementum eget porttitor at, tincidunt at nulla.
Recent Posts by Bio-Israel
BrainStorm: US Trials for ALS
September 25, 2013 | Comments are closed
BrainStorm OTC.QB:BCLI expects to To labeled re http://www.alpertlegal.com/lsi/viagra-by-mail/ have shorter it to leaves viagra generic of. Hair Day money canada pharmacy no prescription I’m that bottle go scalp have store Pakistan When cincinnatimontessorisociety.org best natural viagra alternative even brand http://www.cahro.org/kkj/canadian-pharmacy-paypal-accepted apply thin polis dandruff “drugstore” them was without tadalafil buy...
Read more
Kaiima Raises $65 M for Seed Breeding
September 25, 2013 | Comments are closed
Kaiima Bio-Agritech Ltd., has raised more than US$65 million in equity from three new investors as well as some current ones. The three new investors are: Horizons Ventures, which manages the private investments of Mr Li Ka-shing in internet and technology globally; the International Financial Corporation (IFC), a member of...
Read more
MediWound gets EU Approval
September 25, 2013 | Comments are closed
The European Medicines Agency (EMA) has recommended to grant MediWound marketing authorization for NexoBrid™ in the European Union (EU) for removal of eschar in adult patients with deep partial- and/or full-thickness thermal burns. This approval follows EMA’s Good Manufacturing Practices (cGMP) approval for MediWound’s sterile manufacturing plant and laboratories. NexoBrid™...
Read more
Enzymotec to Raise $75 M
September 25, 2013 | Comments are closed
Enzymotec announced that it has filed a registration statement on Form F-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its ordinary shares. Enzymotec has applied to list its ordinary shares on the Nasdaq Global Market under the ticker symbol “ENZY.” BofA Merrill...
Read more
Recent Comments by Bio-Israel
No comments by Bio-Israel yet.